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Abstract
Background: Polycystic Ovary Syndrome (PCOS) is a widespread reproductive disorder characterized by a disruption
of follicular growth and anovulatory infertility. In women with PCOS, follicular growth and ovulation can be induced by
subcutaneous injections of low doses of follicle stimulating hormone (FSH). The aim of this study was to determine the
effect of oral administration of recombinant human FSH (rhFSH) on follicle development in a PCOS murine model.
Moreover, since it is unlikely that intact rhFSH is present into the circulation after oral administration, the biological
activity of a peptide fragment, derived from the predicted enzymatic cleavage sites with the FSH molecule, was
investigated in vitro on cumulus-enclosed oocytes (COCs).
Methods: Female peripubertal mice were injected with dehydroepiandrosterone (DHEA) diluted in sesame oil for 20
consecutive days and orally treated with a saline solution of rhFSH. A control group received only sesame oil and saline
solution. At the end of treatments, blood was analyzed for hormone concentrations and ovaries were processed
for morphological analysis. The presumptive bioactive peptide was added during in vitro maturation of bovine
COCs and the effects on cumulus expansion and on maturation rate were evaluated.
Results: DHEA treatment increased serum levels of testosterone, estradiol and progesterone as well as the percentage
of cystic follicles. Orally administered rhFSH restored estradiol level and reduced the percentage of cystic follicles. Despite
these results indicating a reduction of the severity of PCOS in the mouse model, the presumptive bioactive peptide did
not mimic the effect of rhFSH and failed to induce bovine cumulus expansion and oocyte maturation in vitro.
Conclusions: Although further studies are needed, the present data supports the concept that orally administrated FSH
could attenuate some of the characteristic of PCOS in the mouse model.
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Background
Polycystic Ovary Syndrome (PCOS) is a widespread repro-
ductive and endocrinologic disorder, which accounts for
approximately 80 % of women with anovulatory infertility
[1, 2]. PCOS is characterized by hyperandrogenism and
polycystic ovaries, in addition to anovulation [3]. This
syndrome can also be associated with metabolic issues in-
cluding obesity, insulin resistance, hyperinsulinemia, and
type 2 diabetes mellitus, besides cardiovascular problems,
breast and endometrial cancers, and neurological and psy-
chological effects on quality of life [4, 5].
In affected women, the normal ovarian function is dis-
turbed mostly by hyperandrogenism and by the elevated
serum concentrations of luteinizing hormone (LH, [6, 7]),
thus resulting in multiple small cysts [8, 9]. A nearly uni-
versal finding in PCOS is an increased gonadotropin-
releasing hormone (GnRH) pulse frequency, which favors
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LH production over follicle stimulating hormone (FSH)
[10, 11]. The increased LH subsequently promotes theca
cell production of androgens, while the relative FSH defi-
ciency reduces the ability of granulosa cells to convert
androgen into estrogen and impairs follicle maturation
and ovulation [12].
Ovulation induction protocols can be used to re-
store fertility in PCOS patients [13]. One protocol
involves ovarian stimulation by subcutaneous FSH
injection [13, 14]. However, because of the large num-
ber of small antral follicles that are sensitive to FSH
[15], women with PCOS have a higher risk in devel-
oping ovarian hyper-stimulation syndrome (OHSS) in
response to FSH treatment [16]. To reduce this risk,
low-dose administrations of injectable FSH have been
used [17, 18]. For this purpose, the most appropriate
regime is the step-up protocol, in which the FSH
dose is gradually increased until follicular develop-
ment is observed, and then maintained until follicular
selection is achieved [19, 20].
Regardless of good pregnancy and live birth rates [17],
ovarian stimulation with FSH is actually considered a
second-line treatment for the PCOS patients with infer-
tility [13]. This is mainly due to the lack of an oral for-
mulation, the elevated price, and the potentially severe
adverse effects, such as multiple pregnancy and OHSS
(reviewed in [13]). The basic concern about oral formu-
lation is the low bioavailability of FSH that stem from
stomach enzymatic degradation and poor penetration of
FSH peptides across the intestinal membrane [21, 22].
As a consequence it is clear that the research leading to
improved oral FSH therapy could ultimately lead to the
development of innovative and more comfortable treat-
ments for PCOS.
Androgen-treated rodents have been widely used as
models to study both reproductive and metabolic deficits
of PCOS (reviewed in [23–25]). These studies demon-
strate that dihydroepiandrosterone (DHEA) is able to
induce many of the salient features of the human PCOS
condition, such as hyperandrogenism, insulin resistance,
altered steroidogenesis, acyclicity, abnormal maturation
of ovarian follicles, and anovulation in rodents models
[26–29]. Then the present work aims to assess first of
all, the effect of oral administration of low-dose FSH on
the morphological and endocrine function of the ovaries
of hyperandrogenized mice. Subsequently, since intact
FSH is unlikely to be transferred from the gastrointes-
tinal tract into the circulation, the effect of a minimal
amino acid sequence, derived from the analysis of the
enzymatic cleavage sites, was analyzed on an in vitro sys-
tem of bovine oocyte maturation (IVM). Recombinant
human FSH is commonly used in in vitro maturation to
stimulate meiotic resumption and cumulus expansion
both for research purpose and for application in assisted
reproductive technologies in bovine in vitro embryo pro-
duction [30–34] and its effectiveness is sustained by a
growing body of literature. Moreover, the bovine IVM
model represents a highly standardized protocol [35, 36],
particularly efficient and versatile, which allows at the
same time to limit the use and sacrifice of experimental
animals.
Methods
All procedures were carried out in accredited animal
care facilities at the University of Milan, maintained by
the Center for Laboratory Animal Care. The experi-
mental protocol was approved by the University of
Milan Ethics Committee and by the Responsible for
Laboratory Animal Care veterinarian and in accordance
with National (Italian DLT 27/01/1992 n. 116) and
European (European Directive 86/609/EEC on Animal
Care and use for scientific and other experimental
purposes) legislation.
The chemicals used in this study were purchased from
Sigma Chemical Company (St. Louis, MO, USA) except
for those specifically mentioned.
Hyper-androgenization and hormonal treatment
Female Balb/c mice (Charles River Laboratories Italia
s.r.l., Calco, LC, Italy) were maintained on 12-h light,
12-h dark cycles and given food and water ad libitum.
All experiments were performed using mice at post-
natal day 40 and of weight ranging from 14 to 19 g. In
order to hyper-androgenize mice, daily subcutaneous (SC)
injection of dehydroepiandrosterone (DHEA; 1.2 mg/
mouse/day, derived from 6 mg/100 g body weight [37])
dissolved in 0.1 ml sesame oil were performed for 20
consecutive days. To study the effect of oral administra-
tion of recombinant human FSH on PCOS-induced ani-
mals, three groups of 8 mice each were used (see the
Experimental Design in Table 1). Simultaneously to
DHEA treatment, one group (DHEA+rhFSH) received
0.02 IU of rhFSH (Gonal-F, Merck-Serono, Darmstradt,
Germany) deriving from the dose of 50 IU in women [17]
and recalculated according to the body weight average in
the mouse in a total volume of 0.1 ml of saline solution,
Table 1 Experimental design
Treatments SC injection PO administration
CTRL Sesame oil Saline solution
DHEA DHEA (1.2 mg) Saline solution
DHEA+rhFSH DHEA (1.2 mg) rhFSH
1st week 2nd week 3rd week
0.02 IU 0.03 IU 0.04 IU
Daily sub-cutaneous (SC) injection and per os (PO) administration for each
experimental group composed of 8 mice. The total volume for both the SC
injection and the PO administration is 0.1 ml of sesame oil or of saline solution
respectively. The treatment continued for 20 consecutive days
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administred directly into the stomach of mice via oral
gavage, once a day for 1 week, with progressive increases
of 50 % of initial dose each week for a total of 3 weeks in a
step-up approach (Table 1). A second group (DHEA) was
treated only with DHEA by SC administration and saline
by oral gavage, as previously described. The last group
served as controls (CTRL) and only received sesame oil
subcutaneously and saline solution by oral gavage
throughout the experiment. The body weight of animals
was measured at the beginning and at the end of the 20-
days treatments.
Hormonal analysis of serum
After 20 consecutive days of treatments, blood samples
were collected from each mouse before sacrifice. To sep-
arate serum, blood was kept at 4 °C for 1 h, followed by
two consecutive centrifugations for 10 min at 15000 g at
4 °C. Serum was kept at −20 °C until hormonal assay
was performed. Analysis of Testosterone (T) was per-
formed employing a competitive inhibition enzyme im-
munoassay technique (Mouse Testosterone ELISA Kit,
CSB-E05101m, Cusabio, Hubei Province, China; mini-
mum detectable concentration (minDC) = 0.1 ng/ml;
intra-assay and inter-assay precisions (mean of the per-
centages of coefficients of variation) are both <15 %).
According to the manufacturer’s instructions, no signifi-
cant cross-reactivity or interference between mouse testos-
terone and analogues was observed. Levels of Progesterone
(P4), Estradiol (E2) and LH were measured using a mag-
netic bead immunoassay based on Luminex Multiplex
System (Merck Millipore, Darmstadt, Germany), according
to the manufacturer’s instructions; respectively E2 and P4
were analyzed by the “Steroid/Thyroid Hormone Magnetic
Bead Panel” (# STTHMAG-21K; minDC = 0.02 ng/ml for
E2 and 0.09 ng/ml for P4; intra-assay and inter-assay
precisions are <10 % for both analytes), while the
“Mouse Pituitary Magnetic Bead Panel” (# MPTMAG-
49K; minDC = 1.34 pg/ml; intra-assay precision <15 %
and inter-assay precision <20 %) was used for LH.
Morphological evaluation of ovaries
The ovaries were collected immediately after sacrifice
and fixed in 10 % neutral buffered formalin (Bio-Optica,
Milan, Italy) over night. The ovaries were dehydrated in
a graded series of ethanol, cleared with xylene, embed-
ded in paraffin (Bio-Optica) and serially sectioned at
4 μm. Slices were placed on glass microscope slides in
traceable order, stained with hematoxylin and eosin
(DDK Italia, Vigevano, Italy) and finally analyzed under
light microscopy to assess follicles diameter and mor-
phological features [38].
In order to select a representative follicular population
to be analyzed in each ovary, we considered one slice
every 150 μm (i.e. every 37 sections), resulting in a mean
of 4 slices for each ovary. These slices were used to iden-
tify the antral follicles to be measured. For each follicle,
measurements and morphological evaluation were than
conducted on the neighboring slices containing the
corresponding equatorial section. The follicle diameter
was calculated as the mean distance between opposite
basal membrane portions, while the wall thickness was
calculated as the sum of theca interna and granulosa cell
layers. Averages from three different measurements were
considered. The follicular population was divided in two
classes according to follicle diameter: 150–300 μm (early-
small antral follicles) and >300 μm (large antral follicles)
[39–41]. Moreover the presence of morphological cystic
signs, as previously described [26, 27, 42–44]), were
recorded for each antral follicle. Two investigators per-
formed morphological analysis independently.
Immunoexpression of aromatase cytochrome P450
Indirect immunohistochemistry was carried out to
evaluate the expression and localization of aromatase
cytochrome P450 (P450 arom). Before immunohisto-
chemical staining, sections were routinely deparaffinized,
rehydrated and successively heated in a microwave oven
in 0.01 M citrate buffer. Then sections were incubated
with 10 % (v/v) normal rabbit serum, 0.3 % (v/v) Triton
X-100 and 3 % (w/v) bovine serum albumin (BSA) in
phosphate buffered saline (PBS) for 30 min to block
non-specific binding of secondary antibody. Sections
were incubated overnight at 4 °C with 4 μg/ml of poly-
clonal goat anti-CYP19 (CYP19 (C-16): sc-14245, Santa
Cruz Biotechnologies, Inc, Dallas, TX, USA;) diluted in
PBS with 1 % (w/v) BSA and 0.3 % (v/v) Triton X-100.
Primary antibody was detected by using an Alexa Fluor
488-labeled rabbit anti-goat IgG (diluted 1:1000 in PBS
with 1 % (w/v) of BSA. Negative controls were per-
formed by omitting the primary antibody. The sections
were mounted with an antifade medium Vecta Shield
(Vector Laboratories, Inc., Burlingame, CA, USA) sup-
plemented with 1 μg/ml 4′,6-diamidino-2-phenylindole
(DAPI). Samples were analyzed on an epifluorescence
microscope (Eclipse E600, Nikon Corp., Tokyo, Japan) at
a magnification of 200–400×.
FSH-derived bioactive peptide synthesis
The FSH sequence ([Uniprot: P01225]; www.uniprot.org/
uniprot/P01225; www.rcsb.org/pdb/explore/explore.do?str
uctureId=1XWD) was examined for cleavage sites using
Peptide Cutter (web.expasy.org; [45]), a tool that predicts
potential digestion sites cleaved by pepsin, trypsin and
chymotrypsin. This process resulted in the identification
of a peptide sequence of the beta-subunit that likely
maintains the biological activity of intact FSH and is
composed of amino acids 95–121 (Fig. 1 and Additional
file 1: Figure S1). This sequence possesses the amino
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acid sequence involved in binding to the FSH receptor
[46–48]. The identified peptide of 27 amino acids has
been chemically synthetized (PRIMM Biotech, Milan,
Italy) at a high degree of purity (>95 %) for subsequent
biological evaluations.
Assessment of biological activity of FSH-derived peptide
The activity of the peptide sequence was tested on our
standard in vitro maturation (IVM) protocol [49]. As
biological endpoints, cumulus expansion and meiotic
maturation rate were evaluated at the end of IVM
period [36].
Bovine ovaries were recovered at the abattoir (INALCA
Spa., Ospedaletto Lodigiano, LO, IT 2270M CE, Italy) from
pubertal females (4–8 years old) subjected to routine veter-
inary inspection and in accordance to the specific health
requirements stated in Council Directive 89/556/ECC and
subsequent modifications. Ovaries were transported to the
laboratory within 2 h in sterile saline at 26 °C. All sub-
sequent procedures, unless differently specified, were
performed at 35–38 °C and carried out as previously
described [50]. Cumulus-oocyte complexes (COCs)
were retrieved from mid-sized antral follicles (2–6 mm)
with a 16-gauge needle mounted on an aspiration pump
(COOK-IVF, Brisbane QLD, Australia) in M199 supple-
mented with 20 mM HEPES, 1790 units/L heparin and
0.4 % BSA. After examination under a stereomicro-
scope, only COCs medium-brown in color, with five or
more complete layers of cumulus cells enclosing an
oocyte with finely granulated homogenous ooplasm
were used. Selected COCs were individually cultured
for 24 h in M-199 added with 0.68 mM L-glutamine,
Fig. 1 Map of follitropin beta-subunit cleavage sites from stomach and pancreatic proteases digestion: pepsin, trypsin, chymotrypsin. The image
derives from resource web portals web.expasy.org and databases for protein sequences www.uniprot.org; www.rcsb.org/pdb/). This tool predicts
cleavage sites of selected proteases in a protein sequence, in this case pepsin (Pn1.3), trypsin (Tryps), chymotrypsin (Ch_Lo). In the map, the cleavage
probability of trypsin and chymotrypsin is 70 % at least. Cleavage occurs at the right side (C-terminal direction) of the marked amino acid. Specific
residues for hFSH-receptor binding in the follitropin beta-subunit [48] are identify in red. The highlighted peptide sequence composed of amino acids
95–121 likely maintains the biological activity of intact FSH, based on our in silico analysis, and it was used for in vitro assay
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25 mM NaHCO3, 0.4 % BSA fatty acid free and 0.2 mM
sodium pyruvate in humidified air under 5 % CO2 at
38.5 °C. The basic culture medium was then supple-
mented with 10−1 IU/ml of rhFSH (as in standard IVM
in bovine oocytes [51]) or with the peptide (at the same
molar concentration), or not supplemented (control
group). A picture for each COC was taken before and
at the end of in vitro culture and cumulus expansion
was calculated as ratio between final cumulus area and
initial cumulus area. Cumulus area was measured by
ImageJ 1.48v (National Institute of Health, USA; [52])
tools. Oocytes were then mechanically freed from cu-
mulus cells and fixed in 500 μl of 60 % Methanol in
Dulbecco’s Phosphate Buffered Saline for 30 min at 4 °C.
The oocytes were then stained with 0.5 mg/ml of Propi-
dium Iodide to evaluate meiotic stage by observation at
200–400× under fluorescence microscopy [50]. About
30 COCs were analyzed for each group during three
different runs.
Statistical analysis
Statistical analyses were performed using Prism Graph-
Pad (GraphPad Software, version 6.0f, San Diego, CA,
USA). In vivo data were analyzed by one-way ANOVA,
followed by Fisher’s Least Significant Difference (LSD)
multiple comparison test. Fisher’s exact test was used to
compare the percentages of atretic/cystic follicles on the
total follicle population. Data of cumulus expansion assay
were tested for Gaussian distribution using Kolmogorov-
Smirnov test. Since these data were not normally distrib-
uted, Kruskal-Wallis test, followed by Dunn’s multiple
comparison test was used to analyze the cumulus expan-
sion data. Regardless of the test P values <0.05 were
considered significant.
Results
Body weight increase
To investigate the effect of different hormonal treat-
ments on the body mass, mice were weighted during
experimentation. Before treatment the body mass of
animals was not statistically different between groups
(Fig. 2). Mice increased in weight during the treatment
phase of this experiment but those treated with DHEA
gained approximately 10 % more than controls (Fig. 2).
Hormonal analysis of serum
The effect of low dose administration of rhFSH on the
serum hormonal profiles was evaluated using immuno-
assay techniques. Results are illustrated in Fig. 3. Testos-
terone and P4 concentration were statistically higher in
all the PCOS-induced animals (DHEA treated) com-
pared to CTRL, irrespectively to rhFSH administration
(Fig. 3a and b respectively). E2 analysis revealed that
while DHEA significantly increased serum E2 concentra-
tion compared to CTRL, DHEA+rhFSH treatment was
able to restore E2 concentration statistically similar to
the CTRL (Fig. 3c). Finally DHEA alone or with rhFSH
resulted in a statistical decrease of LH concentration
respect to CTRL (Fig. 3d).
Morphological evaluation of ovaries
To study the potential role of the oral administration of
low doses of rhFSH on follicle development in DHEA-
treated animals, the number of follicles 150–300 μm in
diameter and of follicles >300 μm in diameter was moni-
tored in each ovary. DHEA statistically reduced the
number of small follicles per ovary independently from
rhFSH (Fig. 4a). On the other hand, DHEA in the pres-
ence or absence of rhFSH importantly increases the
number of larger follicles per ovary, but rhFSH attenu-
ated DHEA’s actions, significantly reducing large follicle
population (Fig. 4b).
The number of granulosa cells as assessed by the
thickness of the theca and granulosa cell layers was
decreased by DHEA (P <0.05), irrespective of rhFSH
administration, in the large (>300 μm) follicles (Fig. 5)
but not in 150–300 μm follicles (data not shown).
Finally, morphological signs of progressive follicle atre-
sia and cystic formations were observed (Fig. 6, upper
panel). These include granulosa cell pyknosis (Fig. 6b),
disruption of the basement membrane (indicated by aster-
isks in Fig. 6b, c, d) and granulosa cells layers (pointed out
by white arrows in Figs. 6b and c) as well as invasion of
blood cells, the presence of elongated epithelioid cells in
the inner surface of the follicle wall (indicated by black
arrows in Fig. 6e), macrophages in the cystic fluid (showed
by red arrows in Fig. 6f), and reduction of granulosa cells
layers. DHEA significantly increased the occurrence of
morphological cystic features in antral follicles with a
diameter >300 μm per ovary (Fig. 6, lower panel); the oral
administration of rhFSH in DHEA-treated mice was able
to significantly decrease the percentage of atretic/cystic
signs in large follicles, even if it is still higher than
CTRL (P <0.05). Moreover in the 150–300 μm follicle
Fig. 2 Effect of different hormonal treatments on body weight of mice
at day 0 and 21. Data were analyzed by one-way ANOVA, followed by
Fisher’s LSD multiple comparison test; different letters indicate significant
differences between groups (P <0.05)
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population, rhFSH administration importantly reduced
the percentage of atretic/cystic follicles on total follicular
population compared to DHEA treatment alone (Fig. 7).
Localization of aromatase cytochrome P450
In all ovaries regardless the treatment, P450 aromatase
protein was absent or weak in 150–300 μm early-small
antral follicles (Fig. 8) while was localized in the cyto-
plasm of granulosa cells in >300 μm large antral follicles,
with P450 arom concentrated inside the cytoplasm of
Fig. 4 Effect of hormonal treatments on the number of antral follicles
per ovary. a antral follicles of 150–300 μm in diameter; b antral follicles
>300 μm in diameter. Data were analyzed by one-way ANOVA, followed
by Fisher’s LSD multiple comparison test; in each graph, different letters
indicate significant differences between groups (P <0.05)
Fig. 3 Effect of different hormonal treatments on Testosterone,
Progesterone, Estradiol, and Luteinizing Hormone serum concentration.
a Testosterone; b Progesterone; c Estradiol; d Luteinizing hormone.
Data were analyzed by one-way ANOVA, followed by Fisher’s LSD
multiple comparison test; in each graph, different letters indicate
significant differences between groups (P <0.05)
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mural cells, lying on the basal membrane (Fig. 8) with
little or no staining in the cumulus cells. Control sec-
tions did not exhibit any positive staining.
Cumulus expansion and meiotic maturation rate
evaluation
The biological effect of the peptide derived from in silico
enzymatic digestion of FSH was analyzed on the cumu-
lus expansion and on the maturation rate of bovine
COCs. The peptide did not induce cumulus expansion
(Fig. 9a), since the ratio between cumulus areas after
culture and before culture was similar to that of COCs
cultured in absence of FSH (P >0.05). Moreover the FSH
peptide was not able to promote oocyte maturation
(Fig. 9b), even when used at concentration 100, 1000 or
10000 times higher (data not shown). Moreover, treat-
ment with the peptide concurrently to FSH did not
affect the biological effects, since cumulus expansion
index and maturation rate were comparable to that of
FSH alone (data not shown).
Discussion
Most of the animal models used to understand the de-
velopment of PCOS-related dysfunctions are based on
induced hyperandrogenism [53]. DHEA, an androgen of
mainly adrenal origin, is often increased in women with
PCOS [54]. Therefore DHEA is utilized to induce PCOS
in different rodent models. The dose commonly used
(6 mg/100 g body weight) ensures a hyperandrogenized
status equivalent to that found in women with PCOS
[55]. The treatment that we utilized is commonly used
in mice to induce the PCOS phenotype, characterized by
infertility and ovaries containing more atretic follicles
and follicular cysts [56–58]. Our data confirm the previ-
ous finding that DHEA treatment increased the number
of large follicles (>300 μm of diameter) per ovary,
simultaneously reducing the small antral follicles popula-
tion. In addition to the increase in follicles number, our
results demonstrated that DHEA treatment induced an
increase of the number of large follicles presenting mor-
phological signs of atresia and/or cysts (from 0.0 % in
the Control group to 67.26 % ± 3.5 in the DHEA group).
Motta and colleagues found that mouse cysts had a thin
theca layer and a packed stratum of granulosa cells [55].
These findings are confirmed by our results, since
DHEA treated mice exhibit a reduced thickness of fol-
licular wall (theca interna layer plus granulosa cell layer)
in the large follicles. We observed also that both serum
E2 and P4 levels were increased with induction of cysts
formation. These findings are in agreement with other
authors [26, 28, 59, 60] who observed increase in both
cytochrome P450 17-hydroxylase and steroidogenic
acute regulatory protein (StAR) activities in theca cells
from women with PCOS, suggesting a global enhance-
ment of steroidogenesis. This is also consistent with
studies on cultures of human theca cells derived from
follicles isolated from the ovaries of PCOS and normal
women where it has been demonstrated that PCOS
theca cells produce greater amounts of testosterone, 17-
hydroxyprogesterone and P4 than normal theca cells
[61]. Although the mechanism for LH hypersecretion
described in human PCOS is not entirely clear, some
data suggest that it involves impaired negative feedback
on LH secretion mediated by either high E2 or P4 levels
in women with PCOS [62]. Unexpectedly in our study,
serum LH was decreased while LH over-production is
commonly considered one of the peculiar trait of PCOS
[63]. While in the rat data on the effect of postnatal
treatment with DHEA on LH concentration are re-
ported, although contrasting [28, 29, 64], to the best of
our knowledge this is the first study showing the effect
on LH concentration after 20 days of DHEA administra-
tion in the mouse model.
Moreover, our results reveal that DHEA increased
animal weight at the end of the treatment. These obser-
vations are in agreement with both the wide distribu-
tion of obesity in PCOS-affected women [65] and with
the characterization of the murine model reported in
literature [66].
The therapy of PCOS is focused on ovulation induc-
tion in those desiring pregnancy. This may be achieved
indirectly with clomiphene citrate (CC), which is an oral
selective estrogen receptor modulator which action re-
sults in increases in circulating FSH [13], or directly by
FSH administration. The first line of treatment, CC,
restores ovulation in about 80 %, but will result in
pregnancy in only 35 % of patients [67]. Additionally,
about 25 % of PCOS women do not respond to CC
and are considered to be “clomiphene resistant” [67].
Even though FSH treatment is more effective than CC,
Fig. 5 Effect of different hormonal treatments on the wall thickness.
The effect was evaluated on the population of antral follicles >300 μm of
diameter. Data were analyzed by one-way ANOVA, followed by Fisher’s
LSD multiple comparison test; different letters indicate significant
differences between groups (P <0.05)
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it is still considered a second line of treatment, mainly
because of the lack of oral preparation and the risk of
adverse effects [13, 14]. In order to reduce the risk of
OHSS and multiple pregnancy, low-dose treatment pro-
grams have been successfully implemented [17, 18, 20].
The basic thinking behind this regiment is the “threshold
theory”, which demands the attainment and maintenance
of follicular development with exogenous FSH without
exceeding the threshold requirement of the ovary [67]. A
low starting dose of FSH (usually 50–75 IU) is used for 7–
14 days and, if necessary, a weekly 50 % increment of the
initial or previous amount is administered until follicular
development is initiated [17].
In our study we investigated the possibility of FSH oral
administration. Gonadotropins, as most of the drugs
constituted by protein formulations, are traditionally de-
livered via intramuscular, subcutaneous, or intravenous
routes because of their reduced oral bioavailability. This
is mainly due to the fact that peptides can be readily
degraded and pass poorly through the intestinal mucosa
[68, 69]. On the other hand, to the best of our know-
ledge this is the first study reporting that an oral admin-
istration of a low dose of rhFSH is able to ameliorate
some peculiar features of PCOS in hyper-androgenized
mice with treatment using higher doses potentially being
more effective. However, this remains to be determined.
Fig. 6 Effect of different hormonal treatments on the percentage of follicles presenting atretic/cystic signs. Upper panel Representative images of
typical morphological changes in antral follicle walls of ovaries isolated from controls (a) compared to DHEA-treated mice (b, c, d, e, f), stained
with hematoxylin and eosin. In the control (a) theca externa, theca interna, basal membrane and granulosa cells layers appear normal. b, c and d
represent progressive changes associated with follicular atresia (ie. pyknosis, disruption of the basement membrane (asterisks) and of granulosa
layers (white arrows) and invasion of blood cells). Cystic features are described by thin and elongated epithelioid cells in the inner surface of the
wall (e, black arrows) and macrophages in the cystic fluid (f, red arrows). Bar = 50 μm. Lower panel The effect of different hormonal treatment was
evaluated on the population of antral follicles >300 μm of diameter. Data were analyzed by one-way ANOVA, followed by Fisher’s LSD multiple
comparison test; different letters indicate significant differences between groups (P <0.05)
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During the first week, we orally administered 0.02 IU/
die of rhFSH, which was derived from the dose of 50 IU
in women and recalculated according to the average
body weight in the mouse. The orally administered
rhFSH was able both to reduce the number of large an-
tral follicles and at the same time to maintain their via-
bility, while reducing the percentage of atretic and cystic
signs. The effect of FSH administration on cystic signs
in ovarian follicles has not been extensively investigated,
apart from a study in a Guinea pig model, which demon-
strated that exogenous FSH treatment effectively re-
duced the ovarian cyst formation [70]. In our PCOS
model, the oral administration of rhFSH normalized
estradiol serum concentration. This phenomenon ap-
pears to reflect the follicular distribution after the oral
administration of rhFSH, since rhFSH treated ovaries
have a decrease in large antral follicles number (Fig. 4b)
in favor of an increase in the new population of small
growing healthy follicles (Fig. 7a). Compared to larger
follicles, these smaller growing follicles synthetize and
secrete less E2 than the larger follicles [71, 72], and this
could account for the reduced E2 in the rhFSH treated
mice. Further support from this concept is provided by
the immunohistochemical detection of P450 aromatase
in >300 μm large antral follicle and not in the smaller
follicles. Thus the observed 50 % decrease in serum E2
observed in the rhFSH treated ovaries directly corre-
sponds the 50 % decrease in the number of aromatase
expressing follicles.
Thus rhFSH, even though orally administered, seemed
to be able to partially restore the physiological status of
ovarian follicles considering both morphological and
functional aspects. During estrous cycle, FSH stimulates
proliferation of granulosa cells in primary follicles, and
Fig. 7 Effect of different treatments on atretic/cystic follicles. a Total
number (left) and percentage of atretic/cystic (right) in 150–300 μm
follicles. b Total number (left) and percentage of atretic/cystic (right)
in >300 μm diameter follicles. Percentages of atretic/cystic follicles
were analyzed by Fisher’s exact test; different letters indicate significant
differences between groups (P <0.05)
Fig. 8 Immunohistochemical localization of aromatase cytochrome P450. Aromatase expression progresses along with follicle development. No
or weak aromatase protein was detected in 150–300 μm early-small antral follicles (left). Positive staining was evident in >300 large antral follicles
and more concentrated inside the cytoplasm of mural cells, lying on the basal membrane (central). Control sections did not exhibit any positive
staining (right). Scale bar = 50 μm
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once a follicle reaches a diameter of approximately
150 μm, FSH induces antrum formation and aromatase
activity within the granulosa cells with a gradual increase
in estradiol synthesis [73, 74]. Moreover, our results
demonstrate the feasibility of administering effective go-
nadotropin treatment orally.
However while oral administration is effective, we
hypothesize that intact FSH is unlikely to be trans-
ferred from the gastrointestinal tract into the circula-
tion, even though we cannot exclude it. In the present
study we tested whether a bioactive peptide derived
from FSH is functionally active. From this premise, we
selected an amino acidic sequence derived from the
FSH molecule digestion and containing amino acids
responsible for specific receptor binding. Our results
indicated that the selected peptide (from the amino
acid 95–121 of β-chain) is not able to exert biological
effects (i.e. cumulus expansion and oocyte maturation)
in an in vitro model in the bovine species.
On the other hand World Health Organization has cal-
culated that over 10 % of women are inflicted by infertility
and subfertility (www.who.int). Assisted reproductive tech-
nologies (ART) are well-established treatments, represent-
ing substantial economic and healthcare implications for
patients. Total number of ART cycle per annum will reach
2 million by the end of 2015 with a forecast cost for thera-
peutics market that is estimated in about 8 billion of euros.
This valuation derived from the mean of direct cost of one
fresh ART treatment cycle in several countries [75].
Considering that one treatment cycle is often not enough
to achieve the childbirth, the amount is surely under-
estimated. This framework includes also the thera-
peutic market linked to PCOS considering also that
the pharmaceutical market is evolving in a context of
increasing economic pressure, it demands alternative
approaches [76]. This situation has contributed to a
revival of interest in peptides as potential drug candi-
dates, considering alternative routes of administration.
The peptide drug market is also growing twice as fast
in the worldwide drug market [77]. Certainly peptides
and proteins offer several advantages as compared to
conventional drugs. These include high activity, high
specificity, low toxicity, and minimal non-specific and
drug-drug interactions [22], but the physiological, en-
zymatic and chemical barriers for oral administration
route pose a significant challenge to the delivery of
peptide and protein drugs [76]. Then oral delivery of
peptides and proteins, and in particular of FSH [78], is
currently a topic of intense research, which, together
to the economic implication of ovarian stimulation not
only in PCOS treatment [22, 78], strongly encourages
further investigation in identifying FSH-derived pep-
tides or a combination of peptides that have biologic-
ally activity.
Conclusions
In summary, DHEA treatment induced a global in-
crease of Testosterone, E2 and P4 level confirming data
from previous studies on DHEA-induced PCOS model
in mouse where postnatal treatment of mice with
DHEA for 20 consecutive days resulted in most females
exhibiting follicular cysts with a thin granulosa cell
layer and anovulation, increased numbers of atretic fol-
licles, hyperandrogenism, and altered ovarian steroido-
genesis with elevated serum levels of androgens,
estrogens and progesterone [26, 55–57, 66, 79, 80]. Sev-
eral evidences indicate that androgens modulate follicle
Fig. 9 Effect of culture in presence or absence of FSH and in presence
of the peptide. a The effect was evaluated on ratio between cumulus
oophorus area after 24 h culture and at the collection time. Data were
analyzed by Kruskal-Wallis test, followed by Dunn’s multiple comparison
test; different letters indicate significant differences between groups
(P <0.05). b The effect was evaluated on oocyte maturation rate, as the
ability to reach metaphase II stage of meiosis. Data were analyzed by
one-way ANOVA, followed by Fisher’s LSD multiple comparison test;
different letters indicate significant differences between groups (P <0.05)
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development from the present and from other studies
[81–83]. In particular, androgen-receptor KO mouse
models have been used to establish that androgens ac-
tions through androgen-receptors are actually necessary
for normal ovarian function and female fertility and re-
cently has been demonstrated that androgens regulate
ovarian follicular development by increasing follicle
stimulating hormone receptors [83]. In the present
study FSH treatment restored E2 to the control level
and we hypothesize that this maybe due to FSH ability
to suppress growth of large follicles >300, where aro-
matase is more expressed. However, how FSH affects
DHEA-mediated follicle development in mouse model
is unknown and to the best of our knowledge this is the
first study showing FSH capability to modulate its ac-
tivity. The mechanism involved in this interaction de-
serves certainly to be the subject of future research.
Finally, our results suggest that oral administration of
FSH is able to attenuate some of the characteristic of
PCOS in a hyperandrogenized mouse model. Although
further investigation in identifying FSH-derived peptides
potentially maintaining its proper biological activity are
needed, this research could improve our understanding
of the pathogenesis as well as lead to the development of
innovative, more comfortable and cost effective treat-
ments for PCOS infertility.
Additional file
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